Safety and Tolerability of TAR-200 and Nivolumab in Subjects With Muscle-Invasive Bladder Cancer

NCT03518320 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed

Conditions

Bladder Cancer TNM Staging Primary Tumor (T) T2
Bladder Cancer TNM Staging Primary Tumor (T) T2A
Bladder Cancer TNM Staging Primary Tumor (T) T2B
Bladder Cancer TNM Staging Primary Tumor (T) T3
Bladder Cancer TNM Staging Primary Tumor (T) T3A
Bladder Cancer TNM Staging Primary Tumor (T) T3B
Bladder Cancer TNM Staging Regional Lymph Node (N) N0
Bladder Cancer TNM Staging Regional Lymph Node (N) N1
Bladder Cancer TNM Staging Distant Metastasis (M) M0

Interventions

DRUG: Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200
DRUG: Nivolumab Injection [Opdivo]

Sponsor

Taris Biomedical LLC

Collaborators

[object Object]